Conference Coverage

Many VTE patients live in fear of the next event

 

Key clinical point: Consider asking VTE patients how living with their disease affects them from an emotional standpoint.

Major finding: Of 907 survey respondents, 41% said they live in fear of getting another clot “often” or “almost all the time.”

Study details: An online survey of 907 patients aged 18 and older who had experienced a VTE event in the previous 24 months.

Disclosures: The study was supported by Pfizer Independent Grants for Learning & Change, Bristol-Myers Squibb Independent Medical Education, the Joint Commission, the National Eye Institute, and an unrestricted grant from Research to Prevent Blindness. Dr. Feehan disclosed that he has consulted for Pfizer in the past.

Source: Feehan M et al. THSNA 2018, Poster 75.


 

REPORTING FROM THSNA 2018


“If you’re working with patients who believe they don’t have any control over their own care, or if they’re younger or have other disease states, or if they have difficulty getting to and from the hospital, all of those things contribute to elevated emotional harms,” Dr. Feehan said. “That level of emotional harm is clinically relevant.”

After the research team shared the study results with staff of the university’s thrombosis services, clinicians started changing how they interview patients. “For example, instead of asking just ‘Have you experienced any VTE symptoms?’ they now ask things like, ‘How are you feeling?’ or ‘How are things going for you living with the disease?’” Dr. Feehan noted. “Then, patients might say, ‘I’m actually quite worried.’ Such questions can help patients open up about how they feel and foster a better relationship with their provider. A better relationship with their provider might help them feel more in control.”

The study was supported by Pfizer Independent Grants for Learning & Change, Bristol-Myers Squibb Independent Medical Education, the Joint Commission, the National Eye Institute, and an unrestricted grant from Research to Prevent Blindness. Dr. Feehan disclosed that he has consulted for Pfizer in the past.

SOURCE: Feehan et al. THSNA 2018, Poster 75.

Next Article: